Bluejay Diagnostics (NASDAQ:BJDX) & Alphatec (NASDAQ:ATEC) Critical Analysis

Bluejay Diagnostics (NASDAQ:BJDX) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Volatility & Risk

Bluejay Diagnostics has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Alphatec has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Insider and Institutional Ownership

18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 66.4% of Alphatec shares are held by institutional investors. 0.1% of Bluejay Diagnostics shares are held by company insiders. Comparatively, 13.5% of Alphatec shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Bluejay Diagnostics and Alphatec, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1	0	0	0	1.00
Alphatec	1	1	10	0	2.75

Alphatec has a consensus price target of $18.58, indicating a potential upside of 142.60%. Given Alphatec’s stronger consensus rating and higher possible upside, analysts clearly believe Alphatec is more favorable than Bluejay Diagnostics.

Earnings and Valuation

This table compares Bluejay Diagnostics and Alphatec”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85 million	($11.63)	-0.14
Alphatec	$764.16 million	1.54	-$143.36 million	($0.82)	-9.34

Bluejay Diagnostics has higher earnings, but lower revenue than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bluejay Diagnostics and Alphatec’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-144.27%	-115.00%
Alphatec	-15.93%	-1,183.84%	-15.83%

Summary

Alphatec beats Bluejay Diagnostics on 9 of the 13 factors compared between the two stocks.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

About Alphatec

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.